Jump to main content
Jump to site search

Issue 8, 2017
Previous Article Next Article

Discovery of human lactate dehydrogenase A (LDHA) inhibitors as anticancer agents to inhibit the proliferation of MG-63 osteosarcoma cells

Author affiliations

Abstract

Human lactate dehydrogenase A (LDHA) has been identified as a potential therapeutic target in the area of cancer metabolism. Herein, we report the discovery of novel LDHA inhibitors through docking-based virtual screening and biological assays. The primary enzymatic assay suggested that compound 11 targeted LDHA with an IC50 value of 0.33 μM. The in vitro cytotoxic assay demonstrated that compound 11 reduced the growth of MG-63 cancer cells with an EC50 value of 3.35 μM. Finally, we found that compound 11 induced the apoptosis of MG-63 cancer cells in a dose dependent manner, upregulated the oxygen consumption rate (OCR), and decreased the lactate formation and extracellular acidification rate (ECAR) in MG-63 cancer cells. Collectively, our data suggested that compound 11 could be a promising lead for the development of potent LDHA inhibitors.

Graphical abstract: Discovery of human lactate dehydrogenase A (LDHA) inhibitors as anticancer agents to inhibit the proliferation of MG-63 osteosarcoma cells

Back to tab navigation

Publication details

The article was received on 02 May 2017, accepted on 06 Jul 2017 and first published on 07 Jul 2017


Article type: Research Article
DOI: 10.1039/C7MD00222J
Citation: Med. Chem. Commun., 2017,8, 1720-1726
  •   Request permissions

    Discovery of human lactate dehydrogenase A (LDHA) inhibitors as anticancer agents to inhibit the proliferation of MG-63 osteosarcoma cells

    A. Fang, Q. Zhang, H. Fan, Y. Zhou, Y. Yao, Y. Zhang and X. Huang, Med. Chem. Commun., 2017, 8, 1720
    DOI: 10.1039/C7MD00222J

Search articles by author

Spotlight

Advertisements